Agilent Technologies, Inc. A
172.79
(0.05)
(0.03%)
as of 25 Sep
- Market cap
- $49.0B
- P/E
- 33.9×
Follow A
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
Agilent Technologies, Inc. (A) EBITDA
Agilent Technologies, Inc.'s EBITDA for fiscal 2025 was $1.8B, unchanged from fiscal 2024. Over the twelve months to 31 July 2026 it was $1.9B. Over the past ten years it has ranged from $775.0M (fiscal 2015) to $1.9B (fiscal 2022); the current reading is higher than 91% of that period. Agilent Technologies, Inc. ranks 6th of 52 Diagnostics & Research companies by EBITDA.
EBITDA, annual
Annual
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | $1.8B | 1.26% |
| FY2024 | $1.7B | 7.65% |
| FY2023 | $1.6B | (16.23%) |
| FY2022 | $1.9B | 16.01% |
| FY2021 | $1.7B | 44.54% |
| FY2020 | $1.2B | (2.12%) |
| FY2019 | $1.2B | 5.83% |
| FY2018 | $1.1B | 9.32% |
| FY2017 | $1.0B | 18.35% |
| FY2016 | $861.0M | 11.10% |
Quarterly
| Period | EBITDA | Change |
|---|---|---|
| Jul 2026 | $510.0M | 9.44% |
| Apr 2026 | $466.0M | 10.95% |
| Jan 2026 | $420.0M | (18.29%) |
| Oct 2025 | $514.0M | 18.98% |
| 43 more quarters | Free account |
Against its own ten years
Low $775.0M
High $1.9B
Ten-year median
$1.2B
Current reading's percentile
91
EBITDA against peers
| Company | EBITDA |
|---|---|
| IQV IQVIA Holdings Inc. compare | $3.4B |
| DGX Quest Diagnostics Incorporated compare | $2.2B |
| A Agilent Technologies, Inc. | $1.9B |
| IDXX IDEXX Laboratories, Inc. compare | $1.6B |
| MTD Mettler-Toledo International, Inc. compare | $1.3B |
| ILMN Illumina, Inc. compare | $1.2B |
| WAT Waters Corporation compare | $942.8M |
| NTRA Natera, Inc. compare | −$223.9M |
| GH Guardant Health, Inc. compare | −$444.9M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on A
- Revenue
- Net income
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement